ResearcherActive in the last 2 years

Sarah Rohlfing

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8608-0165; OpenAlex author ID A5051481811. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2026: 1 paper

Papers 1

Minimal residual disease assessment through ctDNA facilitates tailored immunotherapy in MSI-high, NTRK1-fusion pancreatic adenocarcinoma. Co-author DOI 10.1093/oncolo/oyag108 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Uwe M. Martens · 1 shared paper, 2026 · strength 0.29
- Paper Minimal residual disease assessment through ctDNA facilitates tailored immunotherapy in MSI-high, NTRK1-fusion pancreat… DOI 10.1093/oncolo/oyag108 ↗
Bence Sipos · 1 shared paper, 2026 · strength 0.29
- Paper Minimal residual disease assessment through ctDNA facilitates tailored immunotherapy in MSI-high, NTRK1-fusion pancreat… DOI 10.1093/oncolo/oyag108 ↗
Stephanie Berger · 1 shared paper, 2026 · strength 0.29
- Paper Minimal residual disease assessment through ctDNA facilitates tailored immunotherapy in MSI-high, NTRK1-fusion pancreat… DOI 10.1093/oncolo/oyag108 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.